公司始建于(yu)2017年,位(wei)于(yu)全國第7大(da)化(hua)工(gong)(gong)園區-東營(ying)港(gang)經濟開發區;集應用(yong)基礎(chu)研究、應用(yong)研究、工(gong)(gong)業化(hua)生產(chan)(chan)、國際化(hua)銷(xiao)售于(yu)-體的國家高新(xin)技術企業;主營(ying):小分子仿制原料(liao)藥與醫藥中(zhong)間體、創新(xin)藥定(ding)制加工(gong)(gong)(CDMO)、功(gong)能性精細(xi)化(hua)學品三大(da)板塊(kuai); 2大(da)生產(chan)(chan)區總占地578畝:仿制原料(liao)藥及中(zhong)間體生產(chan)(chan)區、創新(xin)藥CDM0生產(chan)(chan)區。
公司問題
1.希望(wang)以(yi)7.5%的投資(zi)回報率,收回資(zi)方股權(quan),但資(zi)方估值偏低,達不到預期
2、公司(si)總體戰(zhan)(zhan)略模(mo)糊、經營戰(zhan)(zhan)略模(mo)糊、職能戰(zhan)(zhan)略模(mo)糊
3、組織(zhi)結構亂,崗位責(ze)、權、利(li)不清(qing)
4、留不住優(you)秀(xiu)年輕(qing)員工
方案落地成果
①成功以7.68%的(de)投資(zi)回報率,收回資(zi)方股權(quan)
②設計公司戰(zhan)略、經營戰(zhan)略、職能戰(zhan)略,明確未來(lai)的發展方向
③明確(que)崗位:貴(gui).權、利,并建(jian)立學習型組織
④實(shi)施內部股權(quan)激勵,全(quan)員持股,留下優秀的(de)年(nian)輕人才
⑤較2020年同比產值(zhi)提(ti)升35%達(da)到2.98億,凈利潤(run)到4500萬
⑥2025年創新(xin)藥獲批.上(shang)市后,計(ji)劃產值(zhi)翻三倍(bei)以上(shang)
公(gong)(gong)(gong)(gong)司(si)地址(zhi):惠州公(gong)(gong)(gong)(gong)司(si) | 深圳公(gong)(gong)(gong)(gong)司(si) | 廣東公(gong)(gong)(gong)(gong)司(si) | 上海公(gong)(gong)(gong)(gong)司(si) | 江蘇公(gong)(gong)(gong)(gong)司(si) | 浙江公(gong)(gong)(gong)(gong)司(si) | 湖北公(gong)(gong)(gong)(gong)司(si) | 湖南(nan)公(gong)(gong)(gong)(gong)司(si) | 江西(xi)公司(si) | 東莞松山湖研發中(zhong)心
Copyright ?2021 廣東(dong)遠(yuan)大方略(lve)管理咨詢有限公司